Praxis Precision Medicines, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
PRAX$332.97+19.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Collaboration revenue | $— | $8,553 | $2,447 |
| Operating expenses: | |||
| Research and development | 267,115 | 152,413 | 86,766 |
| General and administrative | 59,083 | 56,305 | 42,054 |
| Total operating expenses | 326,198 | 208,718 | 128,820 |
| Loss from operations | (326,198) | (200,165) | (126,373) |
| Other income: | |||
| Other income, net | 22,930 | 17,346 | 3,096 |
| Total other income | 22,930 | 17,346 | 3,096 |
| Net loss | $(303,268) | $(182,819) | $(123,277) |
| Net loss per share attributable to common stockholders, basic and diluted | $(13.48) | $(10.21) | $(18.69) |
| Weighted average common shares outstanding, basic and diluted | 22,504,676 | 17,906,794 | 6,594,316 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.